pLX304-MARK3 Citations (1)
Originally described in: MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, Gunasekera S, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan V, Bhola P, O'Donnell C, Spitzer B, Stutzke C, Lavallee VP, Hebert J, Krivtsov AV, Melnick A, Paietta EM, Tallman MS, Letai A, Sauvageau G, Pouliot G, Levine R, Marto JA, Armstrong SA, Kentsis A Cancer Discov. 2018 Apr;8(4):478-497. doi: 10.1158/2159-8290.CD-17-1271. Epub 2018 Feb 5. PubMed Journal
Articles Citing pLX304-MARK3
| Articles |
|---|
| TDP-43 dysregulation of polyadenylation site selection is a defining feature of RNA misprocessing in amyotrophic lateral sclerosis and frontotemporal dementia. Arnold FJ, Cui Y, Michels S, Colwin MR, Stockford CM, Ye W, Maheswari Jawahar V, Jansen-West K, Philippe J, Gulia R, Gou Y, Tam OH, Menon S, Situ WG, Cazarez SL, Zandi A, Ehsani KC, Howard S, Dickson DW, Gale Hammell M, Prudencio M, Petrucelli L, Li W, La Spada AR. J Clin Invest. 2025 Jun 2;135(11):e182088. doi: 10.1172/JCI182088. eCollection 2025 Jun 2. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.